20.52USD-1.51%Mkt Cap: 678.70M USDP/E: —Last update: 2026-05-26
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL S…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap678.70M USD
Enterprise Value487.79M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.87M USD
Revenue/Share—
Last Price20.52 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees65
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.18
PEG—
EV/EBITDA-10.01
EV/Revenue—
P/S—
P/B-0.49
EPS (TTM)-1.34
EPS (Forward)-2.70
52W Range
19.458% of range32.44
52W High32.44 USD
52W Low19.45 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE40.34%
ROA-34.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.70M USD
CapEx (TTM)789.00K USD
FCF Margin—
FCF Yield—
Net Debt-249.40M USD
Net Debt/EBITDA5.12
Balance Sheet
Debt/Equity-0.02
Current Ratio38.00
Quick Ratio37.75
Book Value/Sh-44.8520 USD
Cash/Share7.508 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)45.00 USD
Target Range37.00 USD – 62.00 USD
# Analysts5
Ownership
Shares Out.33.43M
Float6.48M
Insiders42.83%
Institutions93.61%
Short Interest
Short Ratio11.8d
Short % Float7.98%
Short % Out.2.65%
Shares Short884.60K
Short (prev mo.)962.44K
Technical
SMA 5024.03 (-14.6%)
SMA 20025.19 (-18.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)59.00K
Avg Vol (10d)38.98K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—